CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 809 enrolled
Drug / intervention
Jada® Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04995887
NCT04995887N/ACompleted
CompareCT.gov

RUBY: Treating Abnormal Postpartum Uterine Bleeding or Postpartum Hemorrhage With the Jada® System - A Post-Market Registry

Alydia Health·observational·Posted Aug 9, 2021·Updated Aug 22, 2022

In Brief

An observational study evaluating Jada® System for Postpartum Hemorrhage. Completed, enrolled 809 participants across 16 sites.

Detailed Summary

The RUBY Study is a multicenter, observational, post-market registry designed to collect observational data on patients treated with the Jada System in the post-market setting.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPostpartum Hemorrhage
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedAug 9, 2021
Enrollment StartOct 1, 2020
Primary CompletionMar 31, 2022
Study CompletionApr 30, 2022
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 4.9 years ago

Interventions

Jada® Systemdevice

The Jada® System is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. It is a teardrop-shaped, soft silicone ring that is placed into the uterus, where gentle suction is applied to cause the uterus to contract and shrink in size, compressing the blood vessels so the bleeding stops.